Skip to main content

Table 5 CMR findings EGPA

From: T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides

  Controls (n = 20) Patients (n = 22) p
LV-EF (%) 65 ± 4 62 ± 12 0.58
LV-EDV (ml) 109 ± 27 124 ± 48 0.38
LV-ESV (ml) 38 ± 13 51 ± 37 0.35
LV-SV 71 ± 15 74 ± 17 0.76
LV-EDD 45 ± 5 48 ± 6 0.06
LA (cm2) 20 ± 3 21 ± 6 0.97
IVS (mm) 10 ± 2 10 ± 2 0.23
PA (mm) 24 ± 4 25 ± 3 0.27
LV mass (g) 85 ± 20 89 ± 25 0.83
LGE per patient - 9 (41%)  
epicardial - 3 (14%)  
intramural - 2 (9%)  
transmural - -  
subendocardial - 4 (18%)  
% LV mass - 7.1 ± 6  
Native T1 (ms) 952 (923–960) 982 (958–1007) 0.003
Post-contrast T1 (ms) 524 (500–529) 481 (462–527) 0.02
ECV (%) 24.5 (23–25) 28 (25–31) <0.001
T2 (ms) 49 (48–51) 53 (50–55) <0.001
  1. All values are n or mean ± SD or interquartile ranges. CMR cardiac magnetic resonance, LV left-ventricular, EF ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, SV stroke volume, EDD end-diastolic diameter, LA left atrium, IVS interventricular septum, PA pulmonary artery, LGE late gadolinium enhancement, ECV extracellular volume